Latest & greatest articles for fluconazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluconazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluconazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluconazole

21. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials (PubMed)

Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials In this metaanalysis of randomized controlled trials (RCTs) we aimed to compare the in vivo and in vitro activity and the safety of per os itraconazole and fluconazole treatment of uncomplicated acute vaginal/vulvovaginal candidiasis in nonpregnant women. We used PubMed, Scopus, Web of Science, and Cochrane Library (...) to identify the studies that were relevant to our metaanalysis RCTs. Six RCTs were included in this study that comprised 1092 enrolled patients with signs and symptoms of vaginal/vulvovaginal candidiasis that was confirmed by microscopy and/or microbiologic cultures that were obtained from the ectocervix and/or vaginal fundus. Overall, there was no difference between itraconazole and fluconazole regarding clinical cure and improvement at the first and second scheduled visit assessments (pooled odds ratio

2008 EvidenceUpdates

22. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials

Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis (...) of randomized controlled trials Pitsouni E, Iavazzo C, Falagas M E CRD summary This review assessed the effectiveness and safety of oral itraconazole and fluconazole for uncomplicated acute vaginal and vulvovaginal candidiasis in non pregnant women, concluding that both regimens had similar effectiveness and safety. The reliability of the conclusion was uncertain given the poor quality of the included studies. Authors' objectives To assess the effectiveness and safety of oral itraconazole and fluconazole

2008 DARE.

23. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia

Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia Collins CD, Ellis JJ, Kaul DR Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of posaconazole in comparison with fluconazole or itraconazole for the treatment of patients with prolonged neutropenia. The authors concluded that posaconazole was the most cost-effective strategy over either

2008 NHS Economic Evaluation Database.

24. Recurrent tinea versicolor: treatment with itraconazole or fluconazole?

Recurrent tinea versicolor: treatment with itraconazole or fluconazole? BestBets: Recurrent tinea versicolor: treatment with itraconazole or fluconazole? Recurrent tinea versicolor: treatment with itraconazole or fluconazole? Report By: Anastasia Pantazidou, Marc Tebruegge - Senior House Officer, Department of Paediatrics, Specialist Registrar, Department of Paediatric Infectious Diseases respectively Search checked by Bob Phillips - Section Editor, Archimedes, Archives of Disease in Childhood (...) Institution: North Middlesex Hospital, London and St Mary's Hospital, London, UK Date Submitted: 26th October 2007 Date Completed: 26th October 2007 Last Modified: 26th October 2007 Status: Green (complete) Three Part Question In [a child/adolescent with tinea versicolor] is [oral itraconazole more effective than oral fluconazole] as [regards cure]? Clinical Scenario A 14-year-old girl is seen in the paediatric outpatient department. She was referred by her general practitioner (GP) with persistent tinea

2007 BestBETS

25. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. (PubMed)

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. Invasive fungal infections are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation.In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy. The primary end point (...) was the incidence of proven or probable invasive fungal infections from randomization to day 112 of the fixed treatment period of the study.Of a total of 600 patients, 301 were assigned to posaconazole and 299 to fluconazole. At the end of the fixed 112-day treatment period, posaconazole was found to be as effective as fluconazole in preventing all invasive fungal infections (incidence, 5.3% and 9.0%, respectively; odds ratio, 0.56; 95 percent confidence interval [CI], 0.30 to 1.07; P=0.07) and was superior

2007 NEJM

26. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (Full text)

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections.In this randomized, multicenter study involving evaluators who were unaware of treatment assignments, we compared the efficacy and safety of posaconazole with those of fluconazole or itraconazole as prophylaxis (...) for patients with prolonged neutropenia. Patients received prophylaxis with each cycle of chemotherapy until recovery from neutropenia and complete remission, until occurrence of an invasive fungal infection, or for up to 12 weeks, whichever came first. We compared the incidence of proven or probable invasive fungal infections during treatment (the primary end point) between the posaconazole and fluconazole or itraconazole groups; death from any cause and time to death were secondary end points.A total

2007 NEJM PubMed

27. Anidulafungin versus fluconazole for invasive candidiasis. (PubMed)

Anidulafungin versus fluconazole for invasive candidiasis. Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis.Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary (...) efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points.Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment

2007 NEJM

28. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. (PubMed)

A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. Invasive candida infections are a major cause of morbidity and mortality in preterm infants. We performed a multicenter, randomized, double-blind, placebo-controlled trial of fluconazole for the prevention of fungal colonization and infection in very-low-birth-weight neonates.During a 15-month period, all neonates weighing less than 1500 g at birth from eight tertiary Italian neonatal intensive care units (322 (...) infants) were randomly assigned to receive either fluconazole (at a dose of either 6 mg or 3 mg per kilogram of body weight) or placebo from birth until day 30 of life (day 45 for neonates weighing <1000 g at birth). We performed weekly surveillance cultures and systematic fungal susceptibility testing.Among infants receiving fluconazole, fungal colonization occurred in 9.8% in the 6-mg group and 7.7% in the 3-mg group, as compared with 29.2% in the placebo group (P<0.001 for both fluconazole groups

2007 NEJM

29. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis

High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients (...) therapy with fluconazole for patients with suspected or invasive candidiasis in an intensive care unit. The authors concluded that high-dose fluconazole was a relatively cost-effective option, and further clinical trials on its safety and efficacy were warranted. Overall, despite some limitations, a reasonably thorough account of this exploratory cost-effectiveness study was reported. The authors’ conclusions reflect the scope of the analysis and should be considered in this context. Type of economic

2007 NHS Economic Evaluation Database.

30. Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis (Full text)

Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis Article Text Treatment Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis Free Gene Harkless , RN, DNSc, ANRP Statistics from Altmetric.com Sobel JD, Wiesenfeld HC

2006 Evidence-Based Nursing PubMed

31. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants

Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants Uko S, Soghier L M, Vega M, Marsh J, Reinersman G T, Herring L, Dave V A, Nafday S, Brion L P Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of intravenous fluconazole prophylaxis (3 mg/kg) for low birth weight (LBW) babies during periods of antibiotic administration. Fluconazole was administered over 30 minutes, at intervals ranging between every third day and every day (depending

2006 NHS Economic Evaluation Database.

32. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. (PubMed)

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Voriconazole has proven efficacy against invasive aspergillosis and oesophageal candidiasis. This multicentre, randomised, non-inferiority study compared voriconazole with a regimen of amphotericin B followed by fluconazole for the treatment of candidaemia in non-neutropenic patients.Non-neutropenic patients with a positive blood culture (...) for a species of candida and clinical evidence of infection were enrolled. Patients were randomly assigned, in a 2:1 ratio, either voriconazole (n=283) or amphotericin B followed by fluconazole (n=139). The primary efficacy analysis was based on clinical and mycological response 12 weeks after the end of treatment, assessed by an independent data-review committee unaware of treatment assignment.Of 422 patients randomised, 370 were included in the modified intention-to-treat population. Voriconazole was non

2005 Lancet

33. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis

Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis Shorr A F, Chung K, Jackson W L, Waterman P E, Kollef M H CRD summary This review evaluated the effects of fluconazole prophylaxis on fungal infections and mortality in critically ill surgical patients. The authors concluded that prophylactic fluconazole appeared (...) to reduce fungal infections but had no effect on mortality, and that further research is required. Overall, this was a reasonably well-conducted review and the authors' cautious conclusions are likely to be reliable. Authors' objectives To evaluate the effects of fluconazole prophylaxis on fungal infections and mortality in critically ill surgical patients. Searching MEDLINE (1966 to December 2004), EMBASE (1990 to December 2004) and the Cochrane Library were searched using the reported search terms

2005 DARE.

34. The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis

The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

35. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. (PubMed)

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. No safe and convenient regimen has proved to be effective for the management of recurrent vulvovaginal candidiasis.After inducing clinical remission with open-label fluconazole given in three 150-mg doses at 72-hour intervals, we randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluconazole (150 mg) or placebo weekly for six months, followed by six months of observation without (...) therapy. The primary outcome measure was the proportion of women in clinical remission at the end of the first six-month period. Secondary efficacy measures were the clinical outcome at 12 months, vaginal mycologic status, and time to recurrence on the basis of Kaplan-Meier analysis.Weekly treatment with fluconazole was effective in preventing symptomatic vulvovaginal candidiasis. The proportions of women who remained disease-free at 6, 9, and 12 months in the fluconazole group were 90.8 percent, 73.2

2004 NEJM

36. Fluconazole improves survival in septic shock: A randomized double-blind prospective study

Fluconazole improves survival in septic shock: A randomized double-blind prospective study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2003 PedsCCM Evidence-Based Journal Club

37. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. (PubMed)

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. Whereas certain oral antifungal azoles are well documented to have activity against leishmania, data on the efficacy of fluconazole for leishmaniasis are limited. We conducted a controlled trial in Saudi Arabia of fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major.This randomized, double-blind, placebo-controlled trial assessed the efficacy of oral fluconazole, in a dose of 200 (...) mg daily for six weeks, in the treatment of parasitologically confirmed cutaneous leishmaniasis. The primary outcome measure was the time to the complete healing of all lesions.A total of 106 patients were assigned to receive fluconazole, and 103 patients were assigned to receive placebo. Follow-up data were available for 80 and 65 patients, respectively. At the three-month follow-up, healing of lesions was complete for 63 of the 80 patients in the fluconazole group (79 percent) and 22 of the 65

2002 NEJM

38. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. (PubMed)

Fluconazole prophylaxis against fungal colonization and infection in preterm infants. Invasive fungal infection is associated with substantial morbidity and mortality in preterm infants. We evaluated the efficacy of prophylactic fluconazole in preventing fungal colonization and invasive infection in extremely-low-birth-weight infants.We conducted a prospective, randomized, double-blind clinical trial over a 30-month period in 100 preterm infants with birth weights of less than 1000 g (...) . The infants were randomly assigned during the first five days of life to receive either intravenous fluconazole or placebo for six weeks. We obtained weekly surveillance cultures from all patients.The 50 infants randomly assigned to fluconazole and the 50 control infants were similar in terms of birth weight, gestational age at birth, and base-line risk factors for fungal infection. During the six-week treatment period, fungal colonization was documented in 30 infants in the placebo group (60 percent

2001 NEJM

39. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis

Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis Kontoyiannis D P, Bodey G P, Mantzoros C S Authors' objectives To answer two questions. 1. In candidaemic adult patients, does therapy with fluconazole differ from amphotericin B in terms of total mortality, infection (...) -specific mortality, response, late complications, and toxicity? 2. How do the two drugs compare in the treatment of candidaemia caused by various non-albicans Candida species? Searching MEDLINE was searched from January 1966 to May 1999 using the MeSH terms 'candidaemia', 'candidiasis', 'fluconazole', 'amphotericin B', 'antifungal therapy' and 'prospective studies'. The search was restricted to studies published in the English language. References, review articles and abstracts from international

2001 DARE.

40. Impact of an intravenous fluconazole restriction policy on patient outcomes

Impact of an intravenous fluconazole restriction policy on patient outcomes Impact of an intravenous fluconazole restriction policy on patient outcomes Impact of an intravenous fluconazole restriction policy on patient outcomes Burkiewicz J S, Kostiuk K A, Jacobs R A, Guglielmo B J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A prescription guideline to substitute the use of intravenous fluconazole with oral fluconazole, in the treatment of patients with moderate to severe infections. Type of intervention Prescribing guideline. Economic study type Cost-effectiveness analysis (cost-consequences). Study population The study population comprised adult and paediatric patients in a university teaching hospital, who were

2001 NHS Economic Evaluation Database.